1. Show article details.

    BRIEF-Axcella Receives Fourth Patent Covering Emm Compositions

    Reuters – 8:20 AM ET 04/07/2020

    Axcella Health Inc (AXLA): * AXCELLA RECEIVES FOURTH PATENT COVERING EMM COMPOSITIONS Source text for Eikon: Further company coverage:

  2. Show article details.

    Axcella Receives Fourth Patent Covering EMM Compositions

    Business Wire – 8:00 AM ET 04/07/2020

    Newly issued U.S. patent covers elements of Axcella’s muscle program Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, today announced the issuance of U.S. Patent 10,596,136.

  3. Show article details.

    Flagship Pioneering Completes Raising a New $1.1 Billion Capital Pool

    PR Newswire – 9:00 AM ET 04/02/2020

    CAMBRIDGE, Mass. "We're honored to have the strong support of our existing Limited Partners, as well as the interest from a select group of new Limited Partners, to support Flagship's unique form of company origination during this time of unprecedented economic uncertainty," said Noubar Afeyan, Ph.D., Founder and Chief Executive Officer of Flagship Pioneering.

  4. Show article details.

    BRIEF-Axcella Health Q4 Loss Per Share $0.68

    Reuters – 4:21 PM ET 03/23/2020

    Axcella Health Inc (AXLA): * AXCELLA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE. * Q4 LOSS PER SHARE $0.68. * Q4 EARNINGS PER SHARE ESTIMATE $-0.74 -- REFINITIV IBES DATA. * AXCELLA HEALTH (AXLA) - ON TRACK TO REPORT TOP-LINE DATA FOR LEAD CANDIDATES FOR NONALCOHOLIC STEATOHEPATITIS, OVERT HEPATIC ENCEPHALOPATHY IN MID-2020.

  5. Show article details.

    Axcella Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    Business Wire – 4:01 PM ET 03/23/2020

    CAMBRIDGE, Mass. “Axcella made great strides in 2019 as we presented data at preeminent medical congresses, bolstered our intellectual property portfolio, completed our IPO and strengthened our management team and Board of Directors. “Meanwhile, the impacts of the COVID-19 outbreak on our society and in the medical community are far-reaching and rapidly evolving,” continued Mr. Hinshaw.

  6. Show article details.

    BRIEF-Axcella Announces Oral Presentation At 2020 International Conference On Frailty And Sarcopenia Research

    Reuters – 9:08 AM ET 03/05/2020

    Axcella Health Inc (AXLA): * AXCELLA ANNOUNCES ORAL PRESENTATION AT 2020 INTERNATIONAL CONFERENCE ON FRAILTY AND SARCOPENIA RESEARCH Source text for Eikon: Further company coverage:

  7. Show article details.

    BRIEF-Axcella Completes Enrollment Of Subjects In Axa1665-002 Study

    Reuters – 7:49 AM ET 02/26/2020

    Axcella Health Inc (AXLA): * AXCELLA COMPLETES ENROLLMENT OF SUBJECTS IN AXA1665-002 STUDY. * AXCELLA - TOP-LINE DATA FOR AXA1665-002 STUDY EXPECTED IN MID-2020. * AXCELLA - IND SUBMISSION FOR OVERT HEPATIC ENCEPHALOPATHY, INITIATION OF POTENTIAL REGISTRATIONAL PHASE 2B/3 CLINICAL TRIAL PLANNED FOR H2 2020 Source text for Eikon: Further company coverage:

  8. Show article details.

    Axcella Completes Enrollment of Subjects in AXA1665-002 Study

    Business Wire – 7:30 AM ET 02/26/2020

    CAMBRIDGE, Mass. “We continue to be pleased by the speed at which we have been able to enroll subjects in our clinical studies, including AXA1665-002. Axcella plans to investigate AXA1665 as an oral product candidate for overt hepatic encephalopathy, a disease that is associated with amino acid imbalance, dysregulated ammonia metabolism, and muscle wasting.

  9. Show article details.

    Axcella to Present at the SVB Leerink 9th Annual Global Healthcare Conference

    Business Wire – 8:00 AM ET 02/19/2020

    Presentation and webcast to take place at 9:00 a.m. ET on February 26 Axcella, a clinical-stage biotechnology company focused on leveraging endogenous metabolic modulators to pioneer a new approach for treating complex diseases and improving health, today announced that management will be presenting at the SVB Leerink 9th Annual Global Healthcare Conference in New York City on February 26, 2020...

  10. Show article details.

    Flagship Pioneering Announces Ohana Biosciences

    PR Newswire – 6:05 AM ET 01/27/2020

    CAMBRIDGE, Mass. "As parental age increases and demographics shift, we face a growing global crisis in reproductive health, and there's an urgent need to advance science that can tackle growing rates of infertility, inherited disease, and pregnancy complications," said Noubar Afeyan, Ph.D., Co-founder of Ohana and CEO of Flagship Pioneering.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Mar
    23

    AXLA announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.